| Filed On | Filing |
|---|---|
| 13 Oct 2026 | SCHEDULE 13G |
| 30 Sep 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 18 Sep 2026 |
8-K: Other Events
On September 16, 2026, Outlook Therapeutics, Inc. established the wholesale acquisition cost for LYTENAVA™ in the United States of $485 per vial. |
| 02 Sep 2026 |
Form 4: Lundquist Kevin Michael, Chief Financial Officer
Granted 500,000 Employee Stock Option (Right to Buy) |
| 02 Sep 2026 |
Form 3: Lundquist Kevin Michael, Chief Financial Officer
No securities owned |
| 27 Aug 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 19 Aug 2026 | SCHEDULE 13G |
| 18 Aug 2026 | 10-Q |
| 17 Aug 2026 | NT 10-Q |
| 14 Aug 2026 |
Form 4: Jahr Robert Charles, Director
Bought 151,515 shares · Acquired 151,515 Warrants (right to buy) (Open Market Purchase) |
| 14 Aug 2026 | SCHEDULE 13D/A |
| 14 Aug 2026 |
Form 4: Sukhtian Ghiath M., Director and 1 other
Bought 2,525,252 shares ($2.5M) · Acquired 2,525,252 Warrants (right to buy) (Open Market Purchase) |
| 14 Aug 2026 |
Form 4: Kenyon Lawrence A, Director
Bought 101,010 shares · Acquired 101,010 Warrants (right to buy) (Open Market Purchase) |
| 14 Aug 2026 | 424B5 |
| 14 Aug 2026 | 8-K: Other Events |
| 14 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 12 Aug 2026 | 424B5 |
| 12 Aug 2026 | 8-K: Results of Operations and Financial Condition; Other Events |
| 29 Jul 2026 |
Form 4: Sukhtian Faisal Ghiath, Director
Bought 95,398 shares ($100K) |
| 24 Jul 2026 | 8-K: Other Events |
Loading...
